Published July 1997 | Version v1
Journal article

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy

  • 1. Institute of Nuclear Medicine, University Hospital, School of Medicine, Basel (Switzerland)
  • 2. Department of Internal Medicine, University Hospital, School of Medicine, Basel (Switzerland)
  • 3. Department of Radiological Physics, University Hospital, School of Medicine, Basel (Switzerland)

Description

This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTATOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with 111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours. (orig.). With 4 figs., 1 tab

Additional details

Publishing Information

Journal Title
European Journal of Nuclear Medicine
Journal Volume
24
Journal Issue
7
Journal Page Range
p. 792-795.
ISSN
0340-6997
CODEN
EJNMD9